Lenti D

Bluebird bio Inc (NASDAQ: BLUE), a clinical-stage biotechnology company that focuses on therapies for the treatment of severe diseases and cancer, released "highly encouraging" clinical data in late 2017, according to Janney. But that doesn't mean investors should be aggressive buyers...

Shares of bluebird bio Inc (NASDAQ: BLUE) gained more than 200 percent in value last year and investors can expect 2018 to be another "blue-ribbon year" for the stock, according to William Blair. The Analyst Willaim Blair's Raju Prasad initiated coverage of bluebird bio's...